Based on this, this study was conducted to explore the efficacy, safety, and impact on patient survival of PDL1/PD-1 inhibitors and FOLFIRINOX regimen for the treatment of advanced pancreatic cancer, and the findings are now reported as follows. Here, CD274 is linked to pancreatic neoplasm.